Eydie Miller Ellis Selected Research

propan-2-yl 4- (6- (4- (2,5- difluorophenoxy)- 3- hydroxybut- 1- en- 1- yl)- 7- hydroxyoctahydro- 2H- cyclopenta(b)oxepin- 3- yl)butanoate

1/2017

Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eydie Miller Ellis Research Topics

Disease

1	Open-Angle Glaucoma (Glaucoma, Open Angle) 01/2017
1	Ocular Hypertension (Glaucoma, Suspect) 01/2017

Drug/Important Bio-Agent (IBA)

1	propan-2-yl 4- (6- (4- (2,5- difluorophenoxy)- 3- hydroxybut- 1- en- 1- yl)- 7- hydroxyoctahydro- 2H- cyclopenta(b)oxepin- 3- yl)butanoateIBA 01/2017